Restless Legs Syndrome (RLS) is a common complaint among patients on hemodialysis. In the general population, studies have reported a 5-29% incidence, but in patients suffering from insomnia the rate is estimated to be 10-20%. The incidence appears to increase with age and occurs more often in patients with diabetes. RLS rates among hemodialysis patients are considered to be appreciably higher, some 15-40%. Symptoms consist of parasthesias of the lower extremities relieved by movement and is usually worse at night. RLS often starts in childhood and progressively worsens throughout adulthood (1) .
The diagnosis of RLS is often difficult. As the definition of disease is rooted in a patient's description of symptoms, misdiagnosis is common.
It is estimated that the mean delay from presentation to correct diagnosis is two years. In an effort to clarify the symptoms required for diagnosis, the International Restless Legs Syndrome Study Group developed a minimum criteria for the diagnosis of RLS that includes four features: a desire to move the extremities associated with paresthesias/dysethesias; motor restlessness; a worsening of symptoms at rest, and relief with activity, and worsening of symptoms at night. Efforts to identify a more objective means of diagnosing RLS have met with little success (2) . Patients with restless legs syndrome are likely to have an associated disorder, periodic limb movements of sleep (PLMS). This is a disorder characterized by repetitive flexion of the legs during sleep, lasting up to five seconds and occurring in a rhythmical fashion every 20 to 40 seconds. PLMS is common in the general population and, like RLS, is more common in the elderly. Overlap between the two disorders is great, so that it is estimated 80 to 90% of patients with RLS have PLMS as well (3).
The underlying pathophysiology has been the subject of much speculation. Treatments of RLS that have demonstrated benefit would seem to suggest that dopamenergic activity plays a central role in the pathogenesis of the disease. Opiates, L-dopa, and bromocriptine all improve symptoms of RLS; conversely, opiate and dopamenergic blocking agents worsen symptoms. A study using single photon emission computed tomography (SPECT) suggested a deficiency of D2 subtype dopamine receptors in RLS (4) . Recent successful use of D2 agonists in the treatment of RLS as well as worsening of symptoms with D2 antagonists support the theory that this receptor plays a central role in the mechanism of disease (5). The nighttime increases in RLS symptoms are thought to be independent of patient's general inactivity at night. In addition, it is reported that patients who cross time zones exhibit a change in time of onset of symptoms, suggesting a circadian factor influencing symptoms (6) .
A variety of disorders have been associated with RLS and may act to trigger or worsen symptoms. Iron deficiency, uremia, diabetes, and rheumatic disease have all been shown to increase the severity of RLS symptoms.
When RLS occurs following the onset of one of these disorders, it is often considered to be a "secondary" rather than "idiopathic" form of the disease.
It is unclear, however, whether these diseases actually cause RLS or merely exacerbate mild RLS symptoms. Other miscellaneous exposures thought to contribute to RLS symptoms and manifestations include hypoglycemia (7) , excess caffeine ingestion, and pregnancy (8) .
Despite minimal understanding of the etiology of RLS, there are a number of treatments with demonstrated effectiveness.
Opiates, benzodiazepines, levodopa, gabapentin, and clonidine are all effective treatment options. Recently the use of specific dopamingeric agonists, including pergolide, ropinirole, and pramipexole have been shown to be effective, and are recommended as first line therapy in patients with moderate to severe symptoms (6) .
The frequency of RLS in hemodialysis patients has been evident for many years. Studies have consistently found the prevalence to be significantly higher in hemodialysis patients than in the general population. Anemia, uremia, and diabetes are common problems in hemodialysis patients and, as noted previously, are associated with increased RLS symptoms.
The importance of RLS symptoms in hemodialysis patients can hardly be understated. The long period of sitting required to perform a hemodialysis treatment can be excruciating for those with severe symptoms. Premature discontinuation of dialysis therapy and subsequent underdialysis can result. Independent association between premature hemodialysis "sign-offs" and RLS symptoms has been documented in at least one study (9) .
Given the breadth of RLS symptom severity there is no clearly defined RLS management protocol to follow. Cases may be treated with whatever regimen is effective enough to diminish symptoms with the least adverse effects. Management of associated symptoms including decreasing caffeine intake, treating anemia and ensuring adequate dialysis treatments can diminish symptom severity, but will rarely eradicate them completely.
Pharmacological therapy for mild cases is often initiated with benzodiazepines at night. Moderate to severe cases are often treated with one of the dopamine agonists.
Efforts to elucidate the pathophysiology of RLS have yielded ever more specific etiologies of the syndrome and lead to more specific and efficient means of therapy. The lack of objective biochemical or physical markers for the disorder pose the greatest limitation in relieving symptoms, as once diagnosed correctly, effective treatments are abundant. The impact of RLS on hemodialysis patients is especially great, considering it may impact the length of time they can tolerate each hemodialysis treatment. Clinicians should be especially diligent in identifying and treating this patient population, given its unique vulnerabilities.
